Alembic Pharmaceuticals has received tentative approval for generic Ribociclib tablets used in the treatment of breast cancer in the March quarter. The tentative approval by the US Food & Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg.
The medicine is indicated for the treatment of adult patients with a certain type of advanced or metastatic breast cancer in a combination of drug therapy. It is the generic equivalent of Novartis' Kisqali tablets.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
